UCTCURE VanEck Genomics and Healthcare Innovators UCITS ETF Please read important disclosure Close important disclosure true de en false false
CURE

Genomics ETF
VanEck Genomics and Healthcare Innovators UCITS ETF

CURE

Genomics ETF
VanEck Genomics and Healthcare Innovators UCITS ETF

ISIN: IE000B9PQW54 copy-icon
WKN: A3DSGJ copy-icon

Fund Description

Technology is transforming healthcare. Not only are genomic treatments for several diseases becoming more affordable, but also digitalized healthcare is growing fast. VanEck’s Genomics and Healthcare Innovators UCITS ETF invests in the businesses pioneering ways to treat disease and connect with patients.

  • NAV
    $19.45

    as of 23 May 2024
  • YTD RETURNS
    -2.59%

    as of 23 May 2024
  • Total Net Assets
    $7.0 million

    as of 23 May 2024
  • Total Expense Ratio
    0.35%
  • Inception Date
    02 Sep 2022
  • SFDR Classification
    Article 9

Overview

Fund Description

Technology is transforming healthcare. Not only are genomic treatments for several diseases becoming more affordable, but also digitalized healthcare is growing fast. VanEck’s Genomics and Healthcare Innovators UCITS ETF invests in the businesses pioneering ways to treat disease and connect with patients.

  • Invest in genomics companies developing new ways to treat health problems such as genetic conditions, cancer and conditions related to ageing
  • Gain exposure to digital health services providers – delivering easy access to doctors, physiotherapists, nurses and pharmacists
  • Pure-play exposure to companies earning at least half their revenues from genomics- or e-healthcare-related industries
  • Invest in an ETF that screens out companies that violate social norms, derive revenues from controversial weapons, or participate in fossil fuel sectors, nuclear power, civilian firearms or tobacco


Risk Factors: Equity market risk, industry concentration risk, risk of investing in smaller companies, technological risk. Please refer to the

KID

and the Prospectus for other important information before investing.



Underlying Index

MVIS® Global Future Healthcare ESG Index (MVFHCTR)

Fund Highlights

  • Invest in genomics companies developing new ways to treat health problems such as genetic conditions, cancer and conditions related to ageing
  • Gain exposure to digital health services providers – delivering easy access to doctors, physiotherapists, nurses and pharmacists
  • Pure-play exposure to companies earning at least half their revenues from genomics- or e-healthcare-related industries
  • Invest in an ETF that screens out companies that violate social norms, derive revenues from controversial weapons, or participate in fossil fuel sectors, nuclear power, civilian firearms or tobacco


Risk Factors: Equity market risk, industry concentration risk, risk of investing in smaller companies, technological risk. Please refer to the

KID

and the Prospectus for other important information before investing.



Underlying Index

MVIS® Global Future Healthcare ESG Index (MVFHCTR)

Performance

Holdings

Portfolio

Literature

Important Information

 
Capital Requirements Report (CRR) Download
GroMiKV Report Download
VAG Report Download

Index

Index Description

The MVIS Global Future Healthcare ESG Index is a global index that tracks the performance of companies that are involved in the genomic health care and electronic healthcare industries.

Index Key Points

Underlying Index
MVIS® Global Future Healthcare ESG Index (MVFHCTR)

The Index Composition:

The MVIS Global Future Healthcare ESG Index (MVFHCTR) tracks the performance of the largest and most liquid companies that are involved in the genomic health care and electronic healthcare industries. MVFHCTR covers at least 90% of the investable universe and adheres to ESG criteria.

Companies initially eligible for inclusion in Index:

  • Companies involved in genomic health care or electronic healthcare industries. This includes companies with at least 50% (25% forcurrent components) of their revenues from the following sub-themes:
    1. Healthcare therapies based on the targeting or modification of genetic makeup of cells or uses mRNA
    2. Technology platforms that enable the development of genetics-based healthcare therapies
    3. Laboratory equipment or services used to test, code, or develop genetics-based healthcare therapies
    4. Software used to facilitate online medical consultations
    5. E-Commerce pharmacies
    6. Software for the management of medical practices and/or patient records
    7. Outpatient medical IoT devices
  • Market capitalization greater than $150 million
  • Three-month average daily turnover greater than $1 million
  • Minimum trading volume of 250,000 shares each month over last 6 months
  • Company weightings are capped at 8%.

 

MVIS